Cognition Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
08/08/2025 03:45
Cognition Therapeutics Inc CGTX.OQ reported a quarterly adjusted loss of 11 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -18 cents. The mean expectation of three analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -14 cents to -6 cents per share. Reported revenue was zero; analysts expected zero. Cognition Therapeutics Inc's reported EPS for the quarter was a loss of 11 cents. The company reported a quarterly loss of $6.73 million. Cognition Therapeutics Inc shares had risen by 129.5% this quarter and gained 1.4% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 10.3% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.50, about 80.7% above its last closing price of $0.68 This summary was machine generated from LSEG data August 8 at 02:45 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.11 | -0.11 | Met |
| Mar. 31 2025 | -0.11 | -0.14 | Missed |
| Dec. 31 2024 | -0.14 | -0.17 | Missed |
| Sep. 30 2024 | -0.22 | -0.25 | Missed |
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB